You are here

CD34‐positive Cells for Human AKI

A recent STEM CELLS Translational Medicine article from researchers led by Hiroyuki Suzuki (Shonan Kamakura General Hospital, Kamakura, Japan) reports the first‐in‐human phase I/II clinical trial of autologous granulocyte colony‐stimulating factor‐mobilized peripheral blood CD34‐positive cell transplantation for severe acute kidney injury (AKI). The authors note that cell therapy was safely performed, and the patient showed improvement of kidney function without major adverse events during the observation period.